Navigating competitive arenas in rare disease
Treatment choice is beneficial for people living with rare diseases (RDs) and competition can drive important economic advantages for payers.
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Strategy in rare disease requires specialist expertise and understanding. CRA understands the unique challenges that rare disease companies face, and we implement a distinctive approach to help drive their success.
Follow us on LinkedIn: CRA on Rare Disease
CRA’s experience stems from hundreds of rare disease engagements across many therapeutic areas.
Treatment choice is beneficial for people living with rare diseases (RDs) and competition can drive important economic advantages for payers.
US policy has long recognized this challenge, beginning with the Orphan Drug Act of 1983 and continuing with recent exemptions for certain orphan indications...
Annabelle Fowler presents the CRA paper titled “An Analysis of Medicaid CPI Rebates and the Sustainability of U.S. Generic Markets.” Ashutosh Mishra presents...
CRA and leading European payer experts hosted a 30-minute virtual webinar to explore how growing competitive dynamics are reshaping the rare diseases market...